BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 16077977)

  • 1. Preferential inhibition of bone metastases by 5'-deoxy-5-fluorouridine and capecitabine in the 4T1/luc mouse breast cancer model.
    Hiraga T; Hata K; Ikeda F; Kitagaki J; Fujimoto-Ouchi K; Tanaka Y; Yoneda T
    Oncol Rep; 2005 Sep; 14(3):695-9. PubMed ID: 16077977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer.
    Hiraga T; Ueda A; Tamura D; Hata K; Ikeda F; Williams PJ; Yoneda T
    Int J Cancer; 2003 Oct; 106(6):973-9. PubMed ID: 12918079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models.
    Endo M; Shinbori N; Fukase Y; Sawada N; Ishikawa T; Ishitsuka H; Tanaka Y
    Int J Cancer; 1999 Sep; 83(1):127-34. PubMed ID: 10449619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of uridine phosphorylase gene expression by tumor necrosis factor-alpha enhances the antiproliferative activity of the capecitabine intermediate 5'-deoxy-5-fluorouridine in breast cancer cells.
    Wan L; Cao D; Zeng J; Yan R; Pizzorno G
    Mol Pharmacol; 2006 Apr; 69(4):1389-95. PubMed ID: 16397116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
    Fujimoto-Ouchi K; Tanaka Y; Tominaga T
    Clin Cancer Res; 2001 Apr; 7(4):1079-86. PubMed ID: 11309360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
    Takechi T; Okabe H; Ikeda K; Fujioka A; Nakagawa F; Ohshimo H; Kitazato K; Fukushima M
    Oncol Rep; 2005 Jul; 14(1):33-9. PubMed ID: 15944764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.
    Magné N; Fischel JL; Dubreuil A; Formento P; Ciccolini J; Formento JL; Tiffon C; Renée N; Marchetti S; Etienne MC; Milano G
    Clin Cancer Res; 2003 Oct; 9(13):4735-42. PubMed ID: 14581344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine].
    Saeki T; Takashima S
    Gan To Kagaku Ryoho; 1999 Mar; 26(4):447-55. PubMed ID: 10097741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma.
    Zhang SH; Zhang H; He HW; Li L; Li XQ; Zhang YP; Shao RG
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):777-88. PubMed ID: 23975242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy.
    Nishimura G; Terada I; Kobayashi T; Ninomiya I; Kitagawa H; Fushida S; Fujimura T; Kayahara M; Shimizu K; Ohta T; Miwa K
    Oncol Rep; 2002; 9(3):479-82. PubMed ID: 11956613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda.
    Ait-Tihyaty M; Rachid Z; Mihalcioiu C; Jean-Claude BJ
    Breast Cancer Res Treat; 2012 May; 133(1):217-26. PubMed ID: 21915635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.
    Kataoka M; Yamaguchi Y; Moriya Y; Sawada N; Yasuno H; Kondoh K; Evans DB; Mori K; Hayashi S
    Oncol Rep; 2012 Feb; 27(2):303-10. PubMed ID: 22076074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of long-term oral chemotherapy with 5'-deoxy-5-fluorouridine and cyclophosphamide for recurrent breast cancer.
    Iba T; Kidokoro A; Fukunaga M; Sugiyama K; Aihara N; Suda M
    Int J Clin Oncol; 2004 Oct; 9(5):383-7. PubMed ID: 15549589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).
    Ebi H; Sigeoka Y; Saeki T; Kawada K; Igarashi T; Usubuchi N; Ueda R; Sasaki Y; Minami H
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):205-11. PubMed ID: 15844007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity.
    Ait-Tihyaty M; Rachid Z; Larroque-Lombard AL; Jean-Claude BJ
    Invest New Drugs; 2013 Dec; 31(6):1409-23. PubMed ID: 23959266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
    Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes.
    Yasuno H; Kurasawa M; Yanagisawa M; Sato Y; Harada N; Mori K
    Oncol Rep; 2013 Feb; 29(2):451-8. PubMed ID: 23229803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of introduction of dThdPase cDNA on sensitivity to 5'-deoxy-5-fluorouridine and tumor angiogenesis.
    Kim R; Murakami S; Toge T
    Int J Oncol; 2003 Apr; 22(4):835-41. PubMed ID: 12632076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
    Hiraga T; Williams PJ; Ueda A; Tamura D; Yoneda T
    Clin Cancer Res; 2004 Jul; 10(13):4559-67. PubMed ID: 15240548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Discovery and development of novel anticancer drug capecitabine].
    Ishitsuka H; Shimma N; Horii I
    Yakugaku Zasshi; 1999 Dec; 119(12):881-97. PubMed ID: 10630095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.